Get the Stockscreener App
4.72
5.03%
-0.25
Tharimmune Inc stock is traded at $4.72, with a volume of 12.58M.
It is down -5.03% in the last 24 hours and up +191.36% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$4.97
Open:
$4.5
24h Volume:
12.58M
Relative Volume:
3.94
Market Cap:
$21.88M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.3713
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
+249.63%
1M Performance:
+191.36%
6M Performance:
+148.42%
1Y Performance:
+59.46%
1-Day Range:
$4.31
$5.34
1-Week Range:
$1.0805
$6.09
52-Week Range:
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
4.72 | 6.86M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Stock (THAR) Latest News
Tharimmune Inc Inc. (THAR) Price Performance: The Role of Supply and Demand - investchronicle.com
Tharimmune Skyrockets 113%—What’s Fueling This Biotech Breakout? - AInvest
Will Tharimmune’s Latest Breakthrough Impact Its Stock? - StocksToTrade
Tharimmune reports positive results for opioid countermeasure film - Investing.com
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments - Tacoma News Tribune
Using data filters to optimize entry into Tharimmune Inc.Buy Signal & Free Weekly Chart Analysis and Trade Guides - Newser
24-Hour Fentanyl Protection: Tharimmune's New Drug Could Revolutionize Military Defense Against Opioid Threats - Stock Titan
Is Tharimmune Inc. a candidate for recovery playProfit Target & Daily Technical Forecast Reports - Newser
Order flow analysis tools used on Tharimmune Inc.2025 Big Picture & Safe Entry Momentum Tips - Newser
What technical models suggest about Tharimmune Inc.’s comebackOil Prices & High Conviction Buy Zone Alerts - Newser
What recovery options are there for Tharimmune Inc.Stop Loss & Proven Capital Preservation Tips - Newser
How to build a dashboard for Tharimmune Inc. stockPortfolio Gains Report & Fast Gain Stock Trading Tips - Newser
Using data tools to time your Tharimmune Inc. exitWeekly Trading Summary & High Accuracy Trade Alerts - Newser
Sentiment analysis tools applied to Tharimmune Inc.Dollar Strength & AI Enhanced Execution Alerts - Newser
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl - Detroit Free Press
Using AI based signals to follow Tharimmune Inc.2025 Big Picture & Technical Buy Zone Confirmation - Newser
Can machine learning forecast Tharimmune Inc. recoveryEarnings Recap Report & Fast Entry Momentum Alerts - Newser
Analyzing drawdowns of Tharimmune Inc. with statistical toolsTrade Risk Assessment & Weekly High Momentum Picks - Newser
Multi factor analysis applied to Tharimmune Inc.2025 Technical Overview & Weekly Watchlist for Hot Stocks - Newser
Published on: 2025-08-19 06:40:05 - Newser
Chart overlay techniques for tracking Tharimmune Inc.2025 Breakouts & Breakdowns & Community Shared Stock Ideas - Newser
Visualizing Tharimmune Inc. stock with heatmapsJuly 2025 News Drivers & Short-Term High Return Strategies - Newser
News impact scoring models applied to Tharimmune Inc.2025 Price Momentum & Reliable Trade Execution Plans - Newser
Tharimmune prices $1.74 million direct offering - MSN
Will Tharimmune Inc. Recover After Recent DeclineQuarterly Market Review & Step-by-Step Swing Trade Plans - newsimpact.co.kr
Published on: 2025-08-19 05:34:39 - newsimpact.co.kr
Applying Wyckoff theory to Tharimmune Inc. stockFed Meeting & Intraday High Probability Alerts - Newser
Is Tharimmune Inc. showing insider buying2025 Major Catalysts & Real-Time Market Sentiment Alerts - thegnnews.com
What makes Tharimmune Inc. stock price move sharplyPortfolio Performance Summary & Entry Point Confirmation Signals - thegnnews.com
What’s the recovery path for long term holders of Tharimmune Inc.Quarterly Trade Report & Precise Buy Zone Tips - Newser
Chart based analysis of Tharimmune Inc. trendsJuly 2025 Levels & Weekly High Momentum Picks - Newser
Tharimmune Inc. stock trend outlook and recovery pathJuly 2025 Pullbacks & Verified Chart Pattern Signals - Newser
What machine learning models say about Tharimmune Inc.Quarterly Portfolio Review & Verified Momentum Watchlists - Newser
Can Tharimmune Inc. sustain earnings growthAnalyst Downgrade & Reliable Entry Point Trade Alerts - newsyoung.net
Using fundamentals and technicals on Tharimmune Inc.Earnings Beat & AI Enhanced Execution Alerts - Newser
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tharimmune Inc Stock (THAR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parikh Sanam | Director |
Jun 20 '25 |
Buy |
1.45 |
1,000 |
1,450 |
1,770 |
| Appajosyula Sireesh | Chief Executive Officer |
Jun 20 '25 |
Buy |
1.48 |
61,496 |
90,973 |
64,868 |
| Parikh Sanam | Director |
May 15 '25 |
Buy |
1.30 |
770 |
1,001 |
770 |
| MILBY RANDY | CEO |
Dec 19 '24 |
Buy |
2.12 |
4,600 |
9,752 |
17,534 |
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):